Veradermics carries a favorable risk/reward with approximately 16.8% upside to the price target and analyst consensus implying roughly 37% appreciation potential, but the entire thesis rests on a single pipeline asset against a quality profile well below sustainable levels — a setup suited only for a small, cautious position sized for the binary risk.
Thesis pillars
- Single Pipeline Concentration Risk↑Improving
- Quality Below Minimum Threshold→Stable
- Analyst Consensus Signals Large Upside↑Improving
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Mar 30, 2026
Veradermics, Incorporated (MANE) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $140.72: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10. Specifically: High short interest: 16%; Below-average business quality.
Veradermics is a clinical-stage biopharmaceutical company with no approved products, developing VDPHL01, an oral extended-release minoxidil formulation for pattern hair loss affecting approximately 50 million men and 30 million women in the U.S. The company is conducting three... Read more
Sell if holding. Engine safety override at $140.72: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10. Specifically: High short interest: 16%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.2/10, moderate confidence.
Passes 5/8 gates (positive momentum, no SEC red flags, news boost analyst 0.70, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and clean insider activity. Suitability: speculative.
About Veradermics, Incorporated
About Veradermics, Incorporated
Veradermics has three registration-directed clinical trials underway for VDPHL01 — an extended-release oral minoxidil for pattern hair loss — with topline data from the 519-patient male Phase 2/3 trial expected in H1 2026 and the 536-patient male Phase 3 trial in H2 2026. The company completed its IPO in Q1 2026 for $294.8 million in gross proceeds and held $141.9 million in cash and marketable securities at December 31, 2025, following $557.8 million in total gross equity proceeds raised since inception.
Veradermics generates no product revenue and funds operations entirely through equity financings. VDPHL01 is a 505(b)(2) NDA candidate targeting the cash-pay PHL market, where the company estimates the current U.S. treatment opportunity at approximately $9 billion annually across roughly 50 million male and 30 million female patients. Preliminary Phase 2 data in October 2025 showed 90.5% treatment response at four months in the 21-patient male cohort. The commercial model, if VDPHL01 is approved, bypasses pharmacy benefit managers through a direct cash-pay channel supported by a dermatology-focused field force and DTC advertising. Manufacturing supply is planned through contract manufacturing organizations. The earliest expiring patent term for VDPHL01 extends to 2043, supporting long-dated exclusivity.
Show full overview
VDPHL01 represents substantially all of the company's anticipated value, exposing investors to binary clinical and regulatory risk. Net losses reached $70.0 million in 2025 and the accumulated deficit stood at $123.4 million at December 31, 2025. All three registration-directed trials must read out favorably for the company to pursue NDA submission, and the FDA may require additional trials if existing data are deemed insufficient. Failure to secure approval would likely force a curtailment of planned operations, as Veradermics depends on equity financings rather than product revenue to sustain its development program.
See also: Healthcare · Biotechnology
From Veradermics, Incorporated's most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-10-28Recent Developments — Veradermics, Incorporated
Latest news
- NEWS B. Riley Securities Maintains Buy on Veradermics, Raises Price Target to $204 — benzinga Oct 22, 2026 positive
- NEWS B. Riley Raises Price Target on Veradermics to $204 — fiscal.ai Oct 22, 2026 positive
- NEWS Could This Pill Be a Game Changer for Hair Loss? Veradermics Reports Major Breakthrough — benzinga Oct 19, 2026 positive
- NEWS Silence Therapeutics, Disc Medicine, Veradermics And Other Big Stocks Moving Higher On Monday — benzinga Oct 19, 2026 positive
- NEWS Microsoft To Rally Around 25%? Here Are 10 Top Analyst Forecasts For Monday — benzinga Oct 19, 2026 neutral
Generated 2026-10-28T11:58:43Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineVDPHL0110-K Item 1A: 'We currently anticipate that our success will substantially depend on the approval and successful commercialization of VDPHL01, which is our lead product candidate'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $140.72: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10. Specifically: High short interest: 16%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $130.87. Score 5.2/10, moderate confidence.
Analyst target: $148.34 (+5.4% upside). Prior stop was $130.87. Stop-loss: $130.87.
Concentration risk — Pipeline: VDPHL01; Quality below floor (2.5 < 4.0); Value-trap signals (2/5): Margin compression (op margin -33.3%), Negative free cash flow.
Veradermics, Incorporated trades at a P/E of N/A (forward -53.4). TrendMatrix value score: 6.0/10. Verdict: Sell.
13 analysts cover MANE with a consensus score of 4.3/5. Average price target: $171.
What does Veradermics, Incorporated do?Veradermics is a clinical-stage biopharmaceutical company with no approved products, developing VDPHL01, an oral...
Veradermics is a clinical-stage biopharmaceutical company with no approved products, developing VDPHL01, an oral extended-release minoxidil formulation for pattern hair loss affecting approximately 50 million men and 30 million women in the U.S. The company is conducting three registration-directed Phase 2/3 and Phase 3 trials and completed a $294.8 million IPO in Q1 2026 to fund development through anticipated topline readouts.